Date: 2nd June, 2026

FY26 Performance Highlights

Wanbury Limited reported audited financial results for the quarter and full year ended 31st March 2026.

Full Year FY26 Financial Performance

  • Revenue: Not explicitly stated for full year
  • EBITDA: ₹107.7 Crore, up 34.9% YoY from ₹79.8 Crore in FY25
  • EBITDA Margin: 16.5%, up 330 bps from 13.2% in FY25
  • PAT: ₹66.1 Crore, up 116.6% YoY from ₹30.5 Crore in FY25
  • PAT Margin: 10.2%, up 509 bps from 5.1% in FY25
  • EPS: ₹20.55, more than doubled from ₹9.32 in FY25

EBITDA includes Other Income. The growth was driven by revenue growth, favourable product mix, better yields, procurement efficiencies, and process optimization.

Q4 FY26 Financial Performance

| Metric | Q4 FY26 | QoQ Change | YoY Change |

| Revenue | ₹164.6 Cr | +1.3% | -4.3% |

| EBITDA* | ₹30.1 Cr | +11.9% | -4.5% |

| PAT | ₹21.7 Cr | +37.7% | +7.2% |

| PAT Margin | 13.2% | | +150 bps YoY |

*Includes Other Income

  • Gross Margin: Expanded 887 bps YoY to 60.4% in Q4 FY26
  • Gross Profit: Increased 11.1% YoY to ₹99.5 crore in Q4 FY26
  • EBITDA Margin: 18.2%, improved by 14 bps YoY
  • Exceptional Item: One-time charge of ₹3.6 crore relating to implementation of new labour codes

Operational and Business Highlights

New Product Launches:

  • New Anaesthetic API launched from Tanuku facility after CAPEX completion
  • Commercial dispatches to Europe commenced February 2026

Pipeline Development:

  • Upcoming specialty APIs: Dextromethorphan HBr, Rivaroxaban, and Sitagliptin

Regulatory Approvals:

  • Zero observations received in MFDS, Korea inspection (7-9 April 2026)
  • Zero observations received in USFDA inspection at Patalganga facility
  • Zero observations received in ANVISA Brazil inspection
  • ANVISA, Brazil approval secured for Sertraline Form II

Operational Improvements:

  • Continued investment in debottlenecking, process optimization and manufacturing upgrades
  • Improved plant utilization and enhanced product yields
  • SAP HANA S4 implementation to drive operational efficiencies

Formulations Business:

  • Turnaround continues with improved performance
  • New launches across paediatric, nutraceutical, and specialty categories

Q4 FY26 Context

Revenue from operations for Q4 FY26 stood at ₹164.6 crore, compared to ₹172.0 crore in Q4 FY25. The decline was impacted by the crisis in West Asia in late February, which disrupted API export dispatches during March. As a largely export-led business, this affected quarterly revenue.

Management Commentary

Mr. Mohan Rayana, Director, Wanbury Limited, stated:

"FY26 was an important year for Wanbury. We strengthened business fundamentals through operational efficiencies, debottlenecking, balance sheet improvement, and expansion of our API and formulations portfolio. Improved plant utilisation, enhanced product yields, and procurement efficiencies supported better EBITDA margins.

The fourth quarter saw a revenue decline due to the West Asia crisis impacting API export dispatches in March. This aside, we were on track to deliver growth on the back of new product launches in Q4.

A key milestone was the launch of our new Anaesthetic API with commercial dispatches beginning February 2026. Clearing the MFDS, Korea inspection with zero observations validates our compliance systems. We will continue our API growth journey in FY27 with recent launches and a strong pipeline, while the formulations business will operate from a stronger footing supported by new launches and an improved go-to-market strategy."

Company Background

Established in 1988, Wanbury Limited is listed on NSE (Code: WANBURY) and BSE (Code: 524212). The company has a strong global API presence with exports to over 50 countries and a pan-India formulations footprint. Operates USFDA and EUGMP approved facilities at Tanuku, Andhra Pradesh and Patalganga, Maharashtra.

API Portfolio: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic Acid, Paroxetine, Ketamine Hydrochloride, and others in pipeline. Clients include leading global generic players.

Formulations Portfolio: Presence across cough and cold, gynaecology, orthopaedics, nutraceuticals, gastrointestinal, anti-inflammatory, and analgesics.